You can seek FDA approval to launch a generic drug before the expiration of BELVIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ:-

You can seek FDA approval to launch a generic drug before the expiration of BELVIQ XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ XR:-

You can seek FDA approval to launch a generic drug before the expiration of BOSULIF's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BOSULIF's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BOSULIF:-

You can seek FDA approval to launch a generic drug before the expiration of COMPLERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMPLERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMPLERA:-

You can seek FDA approval to launch a generic drug before the expiration of EPIDUO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EPIDUO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EPIDUO:-

You can seek FDA approval to launch a generic drug before the expiration of GLYXAMBI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GLYXAMBI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GLYXAMBI:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of GOCOVRI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GOCOVRI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GOCOVRI:-

You can seek FDA approval to launch a generic drug before the expiration of JENTADUETO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JENTADUETO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JENTADUETO:-

You can seek FDA approval to launch a generic drug before the expiration of JENTADUETO XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JENTADUETO XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JENTADUETO XR:-

You can seek FDA approval to launch a generic drug before the expiration of JEVTANA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JEVTANA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JEVTANA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of LATUDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LATUDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LATUDA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of NESINA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NESINA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NESINA:-

You can seek FDA approval to launch a generic drug before the expiration of NEUPRO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NEUPRO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NEUPRO:-

You can seek FDA approval to launch a generic drug before the expiration of OPSUMIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OPSUMIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OPSUMIT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of POMALYST's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the POMALYST's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on POMALYST:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of SPIRIVA RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPIRIVA RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPIRIVA RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of SPY AGENT GREEN KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPY AGENT GREEN KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPY AGENT GREEN KIT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of TRADJENTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRADJENTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRADJENTA:-

You can seek FDA approval to launch a generic drug before the expiration of TRIJARDY XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRIJARDY XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRIJARDY XR:-

You can seek FDA approval to launch a generic drug before the expiration of XELJANZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELJANZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELJANZ:-

You can seek FDA approval to launch a generic drug before the expiration of XELJANZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELJANZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELJANZ:-

You can seek FDA approval to launch a generic drug before the expiration of XELJANZ XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELJANZ XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELJANZ XR:-

You can seek FDA approval to launch a generic drug before the expiration of ZOMETA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZOMETA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZOMETA:-